Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

Lecture: Current use of systemic therapies in localised disease

Dr Rainy Umbas - University of Indonesia, Jakarta, Indonesia

Lecture: Current use of systemic therapies in localised disease ( Dr Rainy Umbas - University of Indonesia, Jakarta, Indonesia )

Lecture: Current standard of care in advanced disease

Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan

Lecture: Current standard of care in advanced disease ( Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan )

Lecture: Exploring the androgen signalling pathway in CRPC

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Lecture: Exploring the androgen signalling pathway in CRPC ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany;

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany; )

Debate: Will chemotherapy continue to be standard treatment for symptomatic...

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for) ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Lecture: Clinical Perspectives: How far are we from personalising treatment for...

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Lecture: Clinical Perspectives: How far are we from personalising treatment for prostate cancer patients? ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Debate: Will chemotherapy continue to be standard treatment for symptomatic...

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against) ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany )

Lecture: Future strategies and targets for prostate cancer

Dr Kurt Miller - Benjamin Franklin Medical Center Berlin, Germany

Lecture: Future strategies and targets for prostate cancer ( Dr Kurt Miller - Benjamin Franklin Medical Center Berlin, Germany )

Idelalisib shows promising results in patients with double refractory indolent...

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;

$Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )$

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter...

$Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )$

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta...

$New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )$

Aspirin analogues developed for anti-cancer effects on leukaemia

Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK

Aspirin analogues developed for anti-cancer effects on leukaemia ( Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK )

More from ecancer